克里唑蒂尼
间变性淋巴瘤激酶
医学
肺癌
碱性抑制剂
肿瘤科
一线治疗
淋巴瘤
内科学
癌症研究
化疗
恶性胸腔积液
标识
DOI:10.1080/14737167.2024.2421389
摘要
OBJECTIVES: To assess the economic value of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer at medical insurance negotiation prices from the viewpoint of China's health system. METHODS: Based on data from the phase III clinical trial, a three-state partitioned survival model was established. In combination with parameters such as treatment costs, utility values, incidence of adverse reactions, and discount rates, the total incremental cost-effectiveness ratio (ICER) was simulated. RESULTS: The results of the fundamental analysis indicated that the patients in the lorlatinib group expended 709,671 yuan more than did the patients in the crizotinib group did but gained 3.09 quality-adjusted life years (QALYs). The ICER value was 229,782.6 yuan/QALY, which was lower than three times the per capita gross domestic product (GDP) of China. CONCLUSIONS: Compared with crizotinib, lorlatinib may be a cost-effective first-line treatment choice for advanced ALK-positive NSCLC in China.
科研通智能强力驱动
Strongly Powered by AbleSci AI